Julia Scheffel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Julia Scheffel has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Sophia Hober
KTH Royal Institute of Technology
5 shared publications - Sara Kanje
Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, AlbaNova University Centre, SE-114 19, Stockholm, Sweden
2 shared publications - Abdellah Tebani
Normandie Univ, UNIROUEN, AIMS, SysMedLab, CHU Rouen, Department of Metabolic Biochemistry, Referral Center for Lysosomal Diseases, Filière G2M, 76000 Rouen, France
1 shared publication - Adil Mardinoglu
Science for Life Laboratory, KTH – Royal Institute of Technology, Stockholm, Sweden
1 shared publication - Anders Gummesson
Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
1 shared publication Andreas Andersson
AdBIOPRO, Competence Centre for Advanced BioProduction by Continuous Processing Sweden
1 shared publication
Latest Publications
- Open Access
- 26 February 2023
- Published by Elsevier in Journal of Chromatography A
- Vol. 1694, 463902
Calcium-dependent affinity ligands for the purification of antibody fragments at neutral pH
- 26 February 2023
- Published by Elsevier in Journal of Chromatography A
- Vol. 1694, 463902
Open AccessCalcium-dependent affinity ligands for the purification of antibody fragments at neutral pH
- Open Access
- 7 May 2022
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 119 (8) , 2152-2166
Integrated continuous biomanufacturing on pilot scale for acid‐sensitive monoclonal antibodies
In this study, we demonstrated the first, to our knowledge, integrated continuous bioprocess (ICB) designed for the production of acid‐sensitive monoclonal antibodies, prone to aggregate at low pH, on pilot scale. A high cell density perfusion culture, stably maintained at 100 × 106 cells/ml, was integrated with the downstream process, consisting of a capture step with the recently developed Protein A ligand, ZCa; a solvent/detergent‐based virus inactivation; and two ion‐exchange chromatography steps. The use of a mild pH in the downstream process makes this ICB suitable for the purification of acid‐sensitive monoclonal antibodies. Integration and automation of the downstream process were achieved using the Orbit software, and the same equipment and control system were used in initial small‐scale trials and the pilot‐scale downstream process. High recovery yields of around 90% and a productivity close to 1 g purified antibody/L/day were achieved, with a stable glycosylation pattern and efficient removal of impurities, such as host cell proteins and DNA. Finally, negligible levels of antibody aggregates were detected owing to the mild conditions used throughout the process. The present work paves the way for future industrial‐scale integrated continuous biomanufacturing of all types of antibodies, regardless of acid stability.
- 7 May 2022
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 119 (8) , 2152-2166
Open AccessIntegrated continuous biomanufacturing on pilot scale for acid‐sensitive monoclonal antibodies
In this study, we demonstrated the first, to our knowledge, integrated continuous bioprocess (ICB) designed for the production of acid‐sensitive monoclonal antibodies, prone to aggregate at low pH, on pilot scale. A high cell density perfusion culture, stably maintained at 100 × 106 cells/ml, was integrated with the downstream process, consisting of a capture step with the recently developed Protein A ligand, ZCa; a solvent/detergent‐based virus inactivation; and two ion‐exchange chromatography steps. The use of a mild pH in the downstream process makes this ICB suitable for the purification of acid‐sensitive monoclonal antibodies. Integration and automation of the downstream process were achieved using the Orbit software, and the same equipment and control system were used in initial small‐scale trials and the pilot‐scale downstream process. High recovery yields of around 90% and a productivity close to 1 g purified antibody/L/day were achieved, with a stable glycosylation pattern and efficient removal of impurities, such as host cell proteins and DNA. Finally, negligible levels of antibody aggregates were detected owing to the mild conditions used throughout the process. The present work paves the way for future industrial‐scale integrated continuous biomanufacturing of all types of antibodies, regardless of acid stability.
- Open Access
- 1 January 2021
- Published by Elsevier in Journal of Chromatography A
- Vol. 1637, 461843
Highly selective Protein A resin allows for mild sodium chloride-mediated elution of antibodies
- 1 January 2021
- Published by Elsevier in Journal of Chromatography A
- Vol. 1637, 461843
Open AccessHighly selective Protein A resin allows for mild sodium chloride-mediated elution of antibodies
- Top Cited Papers
- 26 November 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 12 (609)
The human secretome
A database provides information on the relative abundances and locations of human proteins that are predicted to be secreted.
- 26 November 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 12 (609)
Top Cited PapersThe human secretome
A database provides information on the relative abundances and locations of human proteins that are predicted to be secreted.
- Open Access
- 17 September 2019
- Published by Taylor & Francis in mAbs
- Vol. 11 (8) , 1492-1501
Optimization of a calcium-dependent Protein A-derived domain for mild antibody purification
As reported here, we developed and optimized a purification matrix based on a Protein A-derived domain, ZCa, displaying calcium-dependent antibody binding. It provides an alternative to the acidic elution conditions of conventional Protein A affinity chromatography for purification of sensitive antibodies and other Fc-based molecules. We describe the multimerization of ZCa to generate a chromatography resin with higher binding capacity. The highest order multimeric variant, ZCaTetraCys, demonstrated a considerably high dynamic binding capacity (35 mg IgG/ml resin) while preserving the specificity for IgG. High recovery was obtained and host cell protein and DNA content in purified fractions proved to be comparable to commercial MabSelect SuRe and MabSelect PrismA. Various elution conditions for use of this domain in antibody purification were investigated. The purification data presented here revealed variations in the interaction of different subclasses of human IgG with ZCaTetraCys. This resulted in diverse elution properties for the different IgGs, where complete elution of all captured antibody for IgG2 and IgG4 was possible at neutral pH. This optimized protein ligand and the proposed purification method offer a unique strategy for effective and mild purification of antibodies and Fc-fusion proteins that cannot be purified under conventional acidic elution conditions due to aggregation formation or loss of function.
- 17 September 2019
- Published by Taylor & Francis in mAbs
- Vol. 11 (8) , 1492-1501
Open AccessOptimization of a calcium-dependent Protein A-derived domain for mild antibody purification
As reported here, we developed and optimized a purification matrix based on a Protein A-derived domain, ZCa, displaying calcium-dependent antibody binding. It provides an alternative to the acidic elution conditions of conventional Protein A affinity chromatography for purification of sensitive antibodies and other Fc-based molecules. We describe the multimerization of ZCa to generate a chromatography resin with higher binding capacity. The highest order multimeric variant, ZCaTetraCys, demonstrated a considerably high dynamic binding capacity (35 mg IgG/ml resin) while preserving the specificity for IgG. High recovery was obtained and host cell protein and DNA content in purified fractions proved to be comparable to commercial MabSelect SuRe and MabSelect PrismA. Various elution conditions for use of this domain in antibody purification were investigated. The purification data presented here revealed variations in the interaction of different subclasses of human IgG with ZCaTetraCys. This resulted in diverse elution properties for the different IgGs, where complete elution of all captured antibody for IgG2 and IgG4 was possible at neutral pH. This optimized protein ligand and the proposed purification method offer a unique strategy for effective and mild purification of antibodies and Fc-fusion proteins that cannot be purified under conventional acidic elution conditions due to aggregation formation or loss of function.